3′-deoxy-3′-18F-fluorothymidine PET imaging of lymphoid tissues in patients with advanced non-small cell lung cancer undergoing anti-programmed cell death-1 therapy

Abstract Background Anti-programmed cell death-1 (anti-PD-1) therapy has become the standard immunotherapy for patients with advanced non-small cell lung cancer (NSCLC). However, little is known about the organs influenced by PD-1 inhibitors on a patient’s tumor immunity. We examined the changes in...

Full description

Saved in:

Bibliographic Details
Main Authors:	Masayuki Sato, Yukihiro Umeda, Tetsuya Tsujikawa, Tetsuya Mori, Akikazu Shimada, Tomoaki Sonoda, Makiko Yamaguchi, Chisato Honjo, Yuko Waseda, Yasushi Kiyono, Tamotsu Ishizuka, Hidehiko Okazawa
Format:	Article
Language:	English
Published:	SpringerOpen 2025-04-01
Series:	EJNMMI Research
Subjects:	18F-FLT PET PD-1 inhibitor Lung cancer Spleen Bone marrow Proliferation
Online Access:	https://doi.org/10.1186/s13550-025-01225-7
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

3′-deoxy-3′-18F-fluorothymidine PET imaging of lymphoid tissues in patients with advanced non-small cell lung cancer undergoing anti-programmed cell death-1 therapy

Similar Items